The Clinical Microbiology Laboratory of the University of Genoa participated, during the year 2003, in an international antimicrobial surveillance program.The collection of isolates was done according to the site of infection and/or type of patient. Four hundred twenty (420) clinical isolates were analyzed during this year and the frequencies of the different pathogens were investigated. A reference centre carried out susceptibility tests. Oxacillin-resistant Staphylococcus aureus represented 47.6% of all S. aureus isolates from blood stream infections and 33.3% of all S. aureus isolated from skin and soft tissue infections in hospitalised patients.These strains showed resistance to most of the antimicrobial agents evaluated, except vancomycin, teicoplanin, quinupristin/dalfopristin and linezolid which registered 100% of susceptibility. Some isolates from blood stream infections such as E. coli demonstrated resistance to ciprofloxacin (23.3%), levofloxacin (20%), and gatifloxacin (16.6%), and Klebsiella pneumoniae was resistant (18%) to all fluoroquinolones tested. Pseudomonas aeruginosa manifested resistance to ciprofloxacin (16.6%), while 27.7% of these strains were resistant both to levofloxacin and gatifloxacin. All the Enterobacter cloacae isolated from blood were susceptible to ciprofloxacin, levofloxacin and gatifloxacin. Haemophilus influenzae and Moraxella catarrhalis collected from community-acquired respiratory tract infections were all inhibited by ciprofloxacin, levofloxacin and gatifloxacin. E. coli isolated from urinary tract infections in hospitalised patients were resistant to ciprofloxacin, levofloxacin and gatifloxacin (2.7%). All Salmonella spp. collected from samples of patients affected by infections of the gastro-intestinal tract were susceptible to all fluoroquinolones. Penicillin resistance in Streptococcus pneumoniae was found in 21.4% of isolates from patients with respiratory tract infections. Fluoroquinolone resistance was very rare among pneumococci except for ciprofloxacin. High rates of resistance to this drug (100%); resistance to levofloxacin and gatifloxacin was detected only in 3.6% of cases while resistance to moxifloxacina was detected in 1.8% of cases. Macrolide resistance rates were around 35% to 41%, tetracycline and trimethoprim/sulfamethoxazole resistance rates were relatively elevated (37.5% and 32.1% resistance respectively).
INTRODUCTION
The importance of antimicrobial resistance among nosocomial and community-acquired pathogens is acknowledged worldwide, welldesigned antimicrobial surveillance programs are therefore of paramount importance in the fight against these microorganisms (1, 3, 4, 6) . These programs are also necessary to provide information on the trend in microbial occurrence in different geographical regions, to identify changes in the spectrum of microbial pathogens causing serious infection and to monitor trends in antimicrobial resistance patterns in nosocomial and community-acquired infections (10, 11, 13, 14) The information obtained from surveillance efforts have the potential to guide therapeutic approaches for serious infections and may have value in the prevention and control of infection and also to defining appropriate control measures for antimicrobial-resistant pathogens (2, 7, 8, 12) . This information has been provided in recent years by several national and international antimicrobial surveillance program (1, (3) (4) (5) . The Laboratory of Clinical Microbiology of the University of Genoa was included in one of these international surveys designed to identify the predominant pathogens and antimicrobial resistance for both nosocomial and community-acquired infections, collecting consecutive isolates from clinically documented infections. The isolates are gathered according to the type of infection and susceptibility tests are carried out in a Central Microbiology Laboratory by reference broth microdilution methods according to NCCLS guidelines (9) . This study reports the antimicrobial susceptibility patterns of a collection of pathogens isolated from in-and out-patients affected by selected infections in Northern Italy.
MATERIAL AND METHODS

Bacterial strains
The collection of isolates was done according to the site of infection and/or type of patient. The contribution of this Laboratory (organism identification, date of isolation, antimicrobial suscepti-bility profile, etc.) included the first 20 consecutive episodes of blood stream infections (BSI) per month from January 2003 to December 2003, 94 consecutive episodes of community-acquired respiratory tract infections (CARTI), 50 consecutive isolates from skin and soft tissue infection (SSTI), 50 consecutive isolates from urinary-tract infections (UTI), 11 consecutive isolates of organisms considered producers of diarrheal diseases (gastroenteritis, GE) and 7 vancomycin-resistant enterococci (VRE) collected during the period January 2003 -December 2003. Just one isolate per patient was included in the study and all isolates were saved on transport swabs and sent to the monitoring center (Iowa, USA) for storage and further characterization by reference identification and susceptibility testing methods.
SUSCEPTIBILITY TESTING
All isolates were tested against antimicrobials by the broth microdilution method according to National Committee for Clinical Laboratory Standards (NCCLS) by the reference laboratory (Iowa, USA); breakpoints for resistance were those recommended by the NCCLS (9). Antimicrobial agents were obtained from their respective manufactures as laboratory grade powder and included penicillins (ampicillin, penicillin, amoxicillin, and oxacillin), b-lactamase inhibitor combinations (amoxicillin-clavulanate, ticarcillin-clavulanate, and piperacillin-tazobactam), cephalosporins (cefepime, cefuroxime, cefotaxime, ceftriaxone, ceftazidime, cefazolin, cefoxitin, cefaclor, and cefixime), carbapenems (imipenem and meropenem), a monobactam (aztreonam), fluoroquinolones (ciprofloxacin, levofloxacin, gatifloxacin, and garenoxacin [formerly BMS 284756]), aminoglycosides (amikacin, gentamicin, and tobramycin), macrolides (erythromycin, azithromycin, and clarithromycin), the oxazolidinone linezolid, the streptogramin quinupristin-dalfopristin, glycopeptides (vancomycin and teicoplanin), and other drugs, such as clindamycin, chloramphenicol, tetracycline, rifampin, and trimethoprim-sulfamethoxazole. Tables from 2 to 7 reported the in vitro activity of the antibiotic tested against the pathogens isolated from the different anatomic sites. Briefly, with respect to strains collected from blood stream infections. S. aureus (Table 2) resulted resistant in about 50% of the cases, including oxacillin, against the antibiotics tested with the exception of glycopeptides, linezolid, quinupristin/dalfopristin, chloramphenicol, tetracycline rifampicin, co-trimoxeazole, and nitrofurantoin which were found active against more than 90% of the bacterial strains. E. faecalis (Table 2) was inhibited by ampicillin, penicillin, linezolid, glycopeptides and nitrofurantoin, while the other compounds were active against about 50% of these strains. E. coli (Table 2 ) resulted susceptible to β-lactamaseresistant antibiotics in more than 70% of the strains. Fluoroquinolones showed activity against more than 75% of the cases while gentamycin inhibited all isolates. K. pneumoniae (Table 2) manifested susceptibility to the great majority of the β−lactam drugs, aminoglycosides, and to a lesser extend to other antibiotics. E. cloacae (Table 2) was found susceptible to cefepime, carbapenems, fluoroquinolones and amikacin, the other molecules were less active against this pathogen. P. aeruginosa (Table 2) as expected was resistant in about 40% of the cases, meropenem was fully inhibitory and ciprofloxacin was active on 83.4% of the strains tested. Penicillin resistance in Streptococcus pneumoniae was found in 21.4% of isolates from patients with respiratory tract infections ( Table 3) . Fluoroquinolone resistance was very rare among pneumococci except for ciprofloxacin, in fact pneumococci showed very high rates of resistance to this drug (100%); resistance to levofloxacin and gatifloxacin was detected only in 3.6% of cases while resistance to moxifloxacin was detected in 1.8% of cases. Macrolide resistance rates were around 35% to 41%, tetracycline and trimethoprim/sulfamethoxazole resistance rates were relatively elevated (37.5% and 32.1% resistance respectively). The other respiratory pathogens, H. influenzae and M. catarrhalis demonstrated susceptibility to all antibiotics tested with the exception of H. influenzae that was inhibited 82% by ampicillin (Table 3) . S. aureus isolated from soft tissue infections (Table 4 ) resulted resistant to oxacillin in the 33.3% of the strains. This level of unsuceptibility was found against many other antibiotics. Non ß-lactam drugs with the exception of macrolides showed satisfactory in vitro activity against this pathogen. Similar results were registered with S. epidermidis with the exception of tetracycline which demonstrated activity on about 50% of the isolated. E. coli collected from UTI (Table 5 ) was in general more widely susceptible to all the antibiotics tested with the exception of cefazolin, tetracycline and trimethoprim/sulfamethoxazole . Salmonella spp. found in gastroenterical tract (Table 6 ) was in general inhibited by all the drugs. Low percentage of susceptible strains were detected when penicillins were tested. Finally vancomycin-resistant enterococci (Table  7) resulted poorly susceptible to the drugs tested with the exception of linezolid and chloramphenicol which inhibited all strains. The present findings indicate a large diffusion of antibiotic resistant strains in nosocomial settings however susceptibility tests also show a significant percentage of pathogens that are inhibited by various antibiotics. Thus continuous national and international surveillance programs can provides accurate and timely data on the incidence of resistance in the major nosocomial pathogens This information must reach the clinicians (publication in national and international journals, Congresses, Meetings, Discussions, etc) in order to rationally influence their prescription habits and improve the outcome of therapy (3-5, 10, 11) . 
RESULTS AND DISCUSSION
